NCT05275439 2026-03-18
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Phase 1 Terminated
Clinical Trials
9 trialsNCT03404193 2026-03-10
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01366612 2026-03-09
FLUBUTBI
Hackensack Meridian Health
Phase 3 Terminated
NCT03772925 2026-03-03
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04328714 2026-02-13
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease
Emory University
Phase 1 Terminated
NCT04160052 2026-02-12
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02381548 2026-01-30
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT05787496 2026-01-28
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Phase 1 Terminated
NCT04266301 2026-01-13
STIMULUS-MDS2
Novartis
Phase 3 Terminated